β-cell lipotoxicity after an overnight intravenous lipid challenge and free fatty acid elevation in African American versus American White overweight/obese adolescents

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages 2062-2069

  Hughan, Kara S ^a,b   Bonadonna, Riccardo C ^c   Lee, SoJung ^a   Michaliszyn, Sara F ^a   Arslanian, Silva A ^a,b  

^a Division of Weight Management and Wellness   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADOLESCENCE; ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; BODY COMPOSITION; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; ETHNIC DIFFERENCE; FAMILY HISTORY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; OBESITY; PANCREAS ISLET DISEASE; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSITY; ADOLESCENT; ADOLESCENT DEVELOPMENT; AFRICAN AMERICANS; BODY MASS INDEX; COHORT STUDIES; CROSS-OVER STUDIES; DIET, HIGH-FAT; EMULSIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MALE; OBESITY; OVERWEIGHT; PENNSYLVANIA; PHOSPHOLIPIDS; SOYBEAN OIL;

EID: 84877696459     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3492     Document Type: Article

References (42)

1. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4):773-795.
2. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S. Youth type 2 diabetes: insulin resistance, β-cell failure, or both? Diabetes Care. 2005;28:638-644.
3. Libman IM, Arslanian SA. Prevention and treatment of type 2 diabetes in youth. Horm Res. 2007;67(1):22-34.
4. Bacha F, Gungor N, Lee S, Arslanian SA. In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? Diabetes Care. 2009;32(1): 100-105.
5. Weiss R, Caprio S. β-Cell function across the spectrum of glucose tolerance in obese youth. Diabetes. 2005;54(6):1735-1743.
6. Saad R, Gungor N, Arslanian S. Progression from normal glucose tolerance to type 2 diabetes in a young girl: longitudinal changes in insulin sensitivity and secretion assessed by the clamp technique and surrogate estimates. Pediatr Diabetes. 2005;6:95-99.
7. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose induced insulin secretion and β-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology. 1990;127:1580-1589.
8. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes. 1995;44:863-870.
9. Zhou YP, Grill V. Long term exposure to fatty acids and ketones inhibits β-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab. 1995;80:1584-1590.
10. Zhou YP, Grill VE. Long term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest. 1994;93:870-876.
11. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity, and insulin secretion. Diabetologia. 1999;42:128-138.
12. Jensen MD. Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolism. Eur Heart J. 2006;suppl 8:B13-B19.
13. Groop LC, Bonadonna RC, Simonson DC, Petrides AS, Shank M, DeFronzo RA. Effect of insulin on oxidative and nonoxidative pathway of free fatty acid metabolism in human obesity. Am J Physiol. 1992;263:E79-E84.
14. Björntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover in obesity. Acta Med Scand. 1969;185:351-356.
15. Arslanian SA, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in African-American children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. Diabetes. 2002;51:3014- 3019.
16. Hannon TS, Bacha F, Lin Y, Arslanian SA. Hyperinsulinemia in African-American adolescents compared with their American White peers despite similar insulin sensitivity. Diabetes Care. 2008;31:1445-1447.
17. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab. 2003;88:2534-2540.
18. Arslanian SA, Bacha F, Saad R, Gungor N. Family history of type 2 diabetes is associated with decreased insulin sensitivity and an impaired balance between insulin sensitivity and insulin secretion in white youth. Diabetes Care. 2005;28:115-119.
19. Tanner JM. Growth and maturation during adolescence. Nutr Rev. 1981;39: 43-55.
20. Bacha F, Gungor N, Arslanian SA. Measures of β-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr. 2008;152:618-621.
21. Burns S, Kelsey S, Arslanian S. Effects of an intravenous lipid challenge and free fatty acid elevation on in vivo insulin sensitivity in African American versus Caucasian adolescents. Diabetes Care. 2009;32:355-360.
22. Lee SJ, Guerra N, Arslanian S. Skeletal muscle lipid content and insulin sensitivity in black versus white obese adolescents: is there a race differential? J Clin Endocrinol Metab. 2010;95:2426-2432.
23. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol. 1983;55:628-634.
24. Arslanian S, Suprasongsin C, Janosky JE. Insulin secretion and sensitivity in black versus white prepubertal healthy children. J Clin Endocrinol Metab. 1997;82:1923-1927.
25. Cali' A, Bonadonna R, Trombetta M, Weiss R, Caprio S. Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab. 2008;93:1767-1773.
26. Mari A, Camastra S, Toschi E, et al. A model for glucose control of insulin secretion during 24 h of free living. Diabetes. 2001;50(suppl 1):S164-S168.
27. Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes. 2002;51(suppl 1):S221-S226.
28. Steil GM, Rebrin K, Janowski R, Darwin C, Saad MF. Modeling β-cell insulin secretion: implications for closed-loop glucose homeostasis. Diabetes Technol Ther. 2003;5:953-964.
29. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control. 1974;19:716-723.
30. Sjaarda L, Lee SJ, Tfayli H, Bacha F, Bertolet M, Arslanian S. Measuring β-cell function relative to insulin sensitivity in youth: does the hyperglycemic clamp suffice? [published online December 28, 2012] Diabetes Care. doi:10.2337/dc12-1508
31. Haffner SM, D'Agostino R, Goff D, et al. LDL size in African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 1999;19:2234-2240.
32. Amery CM, Round RA, Smith JM, Nattrass M. Elevation of plasma fatty acids by ten-hour intralipid infusion has no effect on basal or glucose-stimulated insulin secretion in normal man. Metabolism. 2000;49:450-454.
33. Balent B, Goswami G, Goodloe G, et al. Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects. Ann NY Acad Sci. 2002;967:535-543.
34. Magnan C, Cruciani C, Clement L, et al. Glucose-induced insulin hypersecretion in lipid-infused healthy subjects is associated with a decrease in plasma norepinephrine concentration and urinary excretion. J Clin Endocrinol Metab. 2001;86:4901-4907.
35. Giacca A, Xiao C, Oprescu A, Carpentier A, Lewis G. Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies. Am J Physiol Endocrinol Metab. 2011;300:E255-E262.
36. Paolisso G, Gambardella A, Amato L, et al. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia. 1995;38:1295-1299.
37. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes. 1995;44:1239-1242.
38. Carpentier A, Mittelman S, Bergman R, Giacca A, Lewis G. Prolonged elevation of plasma free fatty acids impairs pancreatic β-cell function in obese nondiabetic humans not in individuals with type 2 diabetes. Diabetes. 2000; 49:399-408.
39. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52:2461-2474.
40. Pleis JR, Lucas JW, Ward BW. Summary health statistics for US adults: National Health Interview Survey, 2008. Vital Health Stat 10. 2009;242:1-157.
41. Edeoga C, Chapp-Jumbo E, Ammons A, Nyenwe E, Dagogo-Jack S. Pathobiology of prediabetes in a biracial cohort (POP-ABC): interim report on early progressors. Diabetes. 2011;60(suppl 1):A375.
42. Carpentier A, Zinman B, Leung N, et al. Free fatty acid-mediated impairment of glucose-stimulated insulin secretion in nondiabetic Oji-Cree individuals from the Sandy Lake community of Ontario, Canada: a population at very high risk for developing type 2 diabetes. Diabetes. 2003;52(6):1485-1495.